Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers

• Main Authors: Laurie Freire Boullosa (Author), Jinthe Van Loenhout (Author), Tal Flieswasser (Author), Christophe Hermans (Author), Céline Merlin (Author), Ho Wa Lau (Author), Elly Marcq (Author), Marlies Verschuuren (Author), Winnok H. De Vos (Author), Filip Lardon (Author), Evelien L. J. Smits (Author), Christophe Deben (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Auranofin (AF) is a potent, off-patent thioredoxin reductase (TrxR) inhibitor that efficiently targets cancer via reactive oxygen species (ROS)- and DNA damage-mediated cell death. The goal of this study is to enhance the efficacy of AF as a cancer treatment by combining it with the poly(ADP-ribose)...